Abstracts tagged "axial spondyloarthritis"

Abstract Number: 430 • 2019 ACR/ARP Annual Meeting
Axial Spondyloarthritis Patients Report Important Impairments in Daily Life and Work Ability – a Web Survey in 472 Patients
Sebastian Ibanez¹, Rianne van Bentum ², Omar Valenzuela ³ and Irene van der Horst-Bruinsma ², ¹Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile
Background/Purpose: Axial spondyloarthritis (axSpA) can be associated with significant burden and impaired work activity. In Chile, several barriers impede adequate treatment, such as insufficient access…
Abstract Number: 592 • 2019 ACR/ARP Annual Meeting
Replacement of Radiographic Sacroilitis by MRI Structural Lesions: What Is the Impact on Classification of Axial Spondyloarthritis in the ASAS Classification Cohort?
Walter P. Maksymowych¹, Pedro Machado ², Robert Lambert ³, Xenofon Baraliakos ⁴, Mikkel Østergaard ⁵, Joachim Sieper ⁶, Stephanie Wichuk ³, Denis Poddubnyy ⁷, Martin Rudwaleit ⁸, Désirée van der Heijde ⁹, Robert B.M. Landewé ¹⁰, Joel Paschke ¹¹, Susanne Juhl Pedersen ¹² and Ulrich Weber ¹³, ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²University College London, London, United Kingdom, ³University of Alberta, Edmonton, Canada, ⁴Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁵Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁶Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁷Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁸Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ⁹Leiden University Medical Center, Leiden, Netherlands, ¹⁰Amsterdam University Medical Center, Amsterdam, Netherlands, ¹¹CARE Arthritis, Edmonton, Canada, ¹²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark, ¹³Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sonderborg, Denmark
Background/Purpose: xClassification of axial spondyloarthritis is based on the application of either an imaging or clinical arm. Radiographic or MRI evidence of sacroiliitis can be…
Abstract Number: 621 • 2019 ACR/ARP Annual Meeting
The Use of Microbial Flow Cytometry to Analyze the Intestinal and Oral Microbiota
Patrick Stauffer¹, Mark Klick ¹, Tammy Martin ¹, James T. Rosenbaum ² and Mark Asquith ¹, ¹Oregon Health and Science University, Portland, OR, ²Devers Eye Institute and Oregon Health & Science University, Portland, OR
Background/Purpose: The role of the microbiome in the pathogenesis of autoimmune disorders such as axial spondyloarthritis (SpA) has been well-established through means of describing gross…
Abstract Number: 1081 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Alexis Ogdie¹, Mei Liu ², Sabrina Rebello ², Angel Cronin ², Blessing Dube ², Robert McLean ², Esther Yi ³, Peter Hur ³ and Philip Mease ⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) share many clinical features but are differentiated by key clinical and molecular characteristics. Patients…
Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting
Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Marina Magrey¹, Victoria Navarro-Compán ², Sandra Garces ³, Xenofon Baraliakos ⁴, David Sandoval ³, Jeffrey Lisse ³, Silvia Santisteban ³, David Adams ³, Fangyi Zhao ³ and Robert Inman ⁵, ¹Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ²University Hospital La Paz, IdiPaz, Madrid, Spain, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…
Abstract Number: 2497 • 2019 ACR/ARP Annual Meeting
Description and Prevalence of Spondyloarthritis in Unselected Patients with Psoriasis, Acute Anterior Uveitis, and Inflammatory Bowel Disease Presenting with Undiagnosed Back Pain
Walter P. Maksymowych¹, Raj Carmona ², Jonathan Chan ³, James Yeung ⁴, Sibel Zehra Aydin ⁵, Liam Martin ⁶, Ariel Masetto ⁷, Dianne Mosher ⁸, Olga Ziouzina ⁶, Stephanie Keeling ⁹, Sherry Rohekar ¹⁰, Rana Dadashova ¹¹, Joel Paschke ¹¹, Amanda Carapellucci ¹¹ and Robert Lambert ¹², ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²McMaster University, Hamilton, Canada, ³Artus Health Clinic, Vancouver, BC, Canada, ⁴Yeung Rheumatology, Vancouver, Canada, ⁵University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, ⁶University of Calgary, Calgary, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Western University, London, ON, Canada, ¹¹CARE Arthritis, Edmonton, Canada, ¹²University of Alberta, Edmonton, Canada
Background/Purpose: There is limited prospective data as to the frequency of axial spondyloarthritis (axSpA) in unselected patients referred to rheumatologists with undiagnosed back pain who…
Abstract Number: 434 • 2019 ACR/ARP Annual Meeting
Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials
Cheng-Chung Wei¹, Theresa Hunter ², Filip Van den Bosch ³, Jessica Walsh ⁴, Uta Kiltz ⁵, Yan Dong ⁶, David Sandoval ⁶, Luis Leon ⁶, Vibeke Strand ⁷ and Xiaoqi Li ², ¹Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ²Eli Lilly and Company, Indianapolis, ³Ghent University Hospital, Ghent, Belgium, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Previous trials have used the Short Form (SF)-36 questionnaire to evaluate the impact of ankylosing spondylitis/radiographic axial spondyloarthritis (AS/r-axSpA) on health-related quality of life…
Abstract Number: 593 • 2019 ACR/ARP Annual Meeting
Performance of the ASAS Classification Criteria Presenting with Undiagnosed Back Pain: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort
Walter P. Maksymowych¹, Raj Carmona ², Jonathan Chan ³, James Yeung ⁴, Sibel Zehra Aydin ⁵, Liam Martin ⁶, Ariel Masetto ⁷, Dianne Mosher ⁸, Olga Ziouzina ⁶, Stephanie Keeling ⁹, Sherry Rohekar ¹⁰, Rana Dadashova ¹¹, Joel Paschke ¹¹, Amanda Carapellucci ¹¹ and Robert Lambert ¹², ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²McMaster University, Hamilton, Canada, ³Artus Health Clinic, Vancouver, BC, Canada, ⁴Yeung Rheumatology, Vancouver, Canada, ⁵University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, ⁶University of Calgary, Calgary, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Western University, London, ON, Canada, ¹¹CARE Arthritis, Edmonton, Canada, ¹²University of Alberta, Edmonton, Canada
Background/Purpose: Classification criteria for axial spondyloarthritis (axSpA) that capture the spectrum of disease present challenges due to the frequency of back pain, the relative infrequency…
Abstract Number: 622 • 2019 ACR/ARP Annual Meeting
Ten-year Atherosclerotic Cardiovascular Disease Risk Scores in Axial Spondyloarthritis versus the General Population: A Cross-sectional Study
Jean Liew¹, John Reveille ², Henna Sawhney ³, Maria Castillo ³, Benjamin Naovarat ⁴, Susan Heckbert ¹ and Lianne Gensler ⁵, ¹University of Washington, Seattle, WA, ²University of Texas McGovern Medical School, Houston, ³University of California in San Francisco, San Francisco, CA, ⁴University of Texas-McGovern Medical School, Houston, TX, ⁵University San Francisco California, San Francisco, CA
Background/Purpose: Cardiovascular morbidity and mortality are increased in axial spondyloarthritis (axSpA). The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend high intensity statin…
Abstract Number: 1084 • 2019 ACR/ARP Annual Meeting
Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration
Lykke Midtbøll Ørnbjerg¹, Stylianos Georgiadis ², Ulf Lindström ³, Anne Gitte Loft ⁴, Adrian Ciurea ⁵, Herman Mann ⁶, Nurullah Akkoç ⁷, Florenzo Iannone ⁸, Eirik Kristianslund ⁹, Anna Mari Hokkanen ¹⁰, Maria José Santos ¹¹, Catalin Codreanu ¹², Carlos Sánchez-Piedra ¹³, Matija Tomsic ¹⁴, Bjorn Gudbjornsson ¹⁵, Irene van der Horst-Bruinsma ¹⁶, Johan Askling ¹⁷, Michael J. Nissen ¹⁸, Karel Pavelka ⁶, Ozgül Gunduz ⁷, Fabiola Atzeni ¹⁹, Joe Sexton ²⁰, Dan Nordström ²¹, Helena Santos ²², Ruxandra IONESCU ²³, Manuel Pombo-Suarez ²⁴, Ziga Rotar ²⁵, Arni Jon Geirsson ²⁶, Marleen van de Sande ¹⁶, Gary Macfarlane ²⁷, Brigitte Michelsen ²⁸, Merete Lund Hetland ¹ and Mikkel Østergaard ²⁹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³University of Gothenburg, Gothenburg, Sweden, ⁴Department of Rheumatology, Aarhus University Hospital., Aarhus, Denmark, ⁵University Hospital Zürich, Zürich, Switzerland, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁷Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, ⁸Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁰Helsinki University Hospital, Helsinki, Finland, ¹¹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Department of Rheumatology, University Medical Centre, Ljubjana, Slovenia, ¹⁵Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁷Karolinska Institutet, Stockholm, Sweden, ¹⁸University Hospital Geneva, Geneva, Switzerland, ¹⁹Department of Medicine, Messina, Italy, ²⁰Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ²¹Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ²²Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ²³SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁴Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ²⁵UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ²⁶Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁷University of Aberdeen, Aberdeen, United Kingdom, ²⁸EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have vastly improved prognosis in patients with axial spondyloarthritis (axSpA). However, many patients treated with TNFi still fail to…
Abstract Number: 1519 • 2019 ACR/ARP Annual Meeting
Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)
Gareth Jones¹, Linda Dean ¹, Ejaz Pathan ² and Gary Macfarlane ¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Toronto Western Hospital, Toronto, Canada
Background/Purpose: In axial spondyloarthritis (axSpA), the clinical benefits of TNF inhibition (TNFi) are well documented although, by design, most studies report average benefits in groups…
Abstract Number: 2503 • 2019 ACR/ARP Annual Meeting
Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial
Frank Behrens¹, Philipp Sewerin ², Eugenio de Miguel ³, Yusuf Patel ⁴, Anastas Batalov ⁵, Eva Dokoupilova ⁶, Christine Kleinmond ⁷, Effie Pournara ⁸, Ankita Shekhawat ⁹, Claudia Jentzsch ¹⁰, Annette Wiedon ¹⁰ and Xenofon Baraliakos ¹¹, ¹CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴Hull University Teaching Hospitals, Hull, United Kingdom, ⁵Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁶MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Uherské Hradiště, Czech Republic, ⁷ClinProject GmbH, Eurasburg, Germany, ⁸Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ⁹Novartis Healthcare Pvt. Ltd., Hyderabad, India, ¹⁰Novartis Pharma GmbH, Nürnberg, Germany, ¹¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany
Background/Purpose: Enthesitis is a common feature of Spondyloarthritis (SpA)1. Enthesitis at the Achilles tendon is an important manifestation with impact on function which is often…
Abstract Number: 557 • 2019 ACR/ARP Annual Meeting
Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey
Theresa Hunter¹, David Sandoval ², Nicola Booth ³, Elizabeth Holdsworth ⁴ and Atul Deodhar ⁵, ¹Eli Lilly and Company, Indianapolis, ²Eli Lilly and Company, Indianapolis, IN, ³Adelphi Real World, Bollington, United Kingdom, ⁴Adelphi Real World, Manchester, England, United Kingdom, ⁵Oregon Health & Science University, Portland, OR
Background/Purpose: To better understand the symptoms, clinical characteristics, treatment patterns, and quality of life (QoL), of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they compare…
Abstract Number: 594 • 2019 ACR/ARP Annual Meeting
Enhanced Performance of the ASAS Classification Criteria by Deletion of Non-Discriminatory Clinical Items: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort
Walter P. Maksymowych¹, Raj Carmona ², Jonathan Chan ³, James Yeung ⁴, Sibel Zehra Aydin ⁵, Liam Martin ⁶, Ariel Masetto ⁷, Dianne Mosher ⁸, Olga Ziouzina ⁶, Stephanie Keeling ⁹, Sherry Rohekar ¹⁰, Rana Dadashova ¹¹, Joel Paschke ¹¹, Amanda Carapellucci ¹¹ and Robert Lambert ¹², ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²McMaster University, Hamilton, Canada, ³Artus Health Clinic, Vancouver, BC, Canada, ⁴Yeung Rheumatology, Vancouver, Canada, ⁵University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, ⁶University of Calgary, Calgary, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Western University, London, ON, Canada, ¹¹CARE Arthritis, Edmonton, Canada, ¹²University of Alberta, Edmonton, Canada
Background/Purpose: xThe ASAS classification criteria for axial spondyloarthritis (axSpA) have overall sensitivity/specificity of 82.9%/84.4% but component imaging and clinical arms differ in performance (66.2%/97.3% and…
Abstract Number: 624 • 2019 ACR/ARP Annual Meeting
Axial Spondyloarthritis: Knowledge, Screening and Referral Practices Amongst Primary Care Providers
Laura Passalent¹, Christopher Hawke ², Jeff Bloom ², Andrew Bidos ³, Soever Leslie ², Y. Raja Rampersaud ¹, Nigil Haroon ⁴ and Robert Inman ⁵, ¹Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, Canada, ³University Health Network, Toronto, Canada, ⁴Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Early recognition is crucial in improving outcomes in patients with axial spondyloarthritis (axSpA). Despite this, there exists long delay between symptom onset and rheumatology…

« Previous Page
1
…
3
4
5
6
7
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].